- Home
- NVST vs DNLI Comparison
NVST vs DNLI Comparison
Compare NVST & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVST | DNLI |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NVST | DNLI |
|---|---|---|
| Price | $26.61 | $23.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $26.46 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.31 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $2,566,500,000.00 | N/A |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $3.55 | $408.85 |
| P/E Ratio | $114.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.77 | $12.58 |
| 52 Week High | $30.42 | $27.30 |
Technical Indicators
Market Signals| Indicator | NVST | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 50.74 |
| Support Level | $24.21 | $18.27 |
| Resistance Level | $27.00 | $27.30 |
| Average True Range (ATR) | 0.76 | 1.34 |
| MACD | -0.10 | -0.30 |
| Stochastic Oscillator | 60.00 | 34.78 |
Price Performance
Historical ComparisonAbout NVST Envista Holdings Corporation
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.